| Chimeric antigen receptor T cells for sustained remissions in leukemia SL Maude, N Frey, PA Shaw, R Aplenc, DM Barrett, NJ Bunin, A Chew, ... New England Journal of Medicine 371 (16), 1507-1517, 2014 | 5670 | 2014 |
| Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia SL Maude, TW Laetsch, J Buechner, S Rives, M Boyer, H Bittencourt, ... New England Journal of Medicine 378 (5), 439-448, 2018 | 4532 | 2018 |
| Chimeric antigen receptor–modified T cells for acute lymphoid leukemia SA Grupp, M Kalos, D Barrett, R Aplenc, DL Porter, SR Rheingold, ... New England Journal of Medicine 368 (16), 1509-1518, 2013 | 4034 | 2013 |
| T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia M Kalos, BL Levine, DL Porter, S Katz, SA Grupp, A Bagg, CH June Science translational medicine 3 (95), 95ra73-95ra73, 2011 | 3141 | 2011 |
| Current concepts in the diagnosis and management of cytokine release syndrome DW Lee, R Gardner, DL Porter, CU Louis, N Ahmed, M Jensen, SA Grupp, ... Blood, The Journal of the American Society of Hematology 124 (2), 188-195, 2014 | 2767 | 2014 |
| ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells DW Lee, BD Santomasso, FL Locke, A Ghobadi, CJ Turtle, JN Brudno, ... Biology of blood and marrow transplantation 25 (4), 625-638, 2019 | 2140 | 2019 |
| Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma AL Yu, AL Gilman, MF Ozkaynak, WB London, SG Kreissman, HX Chen, ... New England Journal of Medicine 363 (14), 1324-1334, 2010 | 1875 | 2010 |
| Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia DL Porter, WT Hwang, NV Frey, SF Lacey, PA Shaw, AW Loren, A Bagg, ... Science translational medicine 7 (303), 303ra139-303ra139, 2015 | 1797 | 2015 |
| Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species MA Goodell, M Rosenzweig, H Kim, DF Marks, MA DeMaria, G Paradis, ... Nature medicine 3 (12), 1337-1345, 1997 | 1406 | 1997 |
| Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo MC Milone, JD Fish, C Carpenito, RG Carroll, GK Binder, D Teachey, ... Molecular therapy 17 (8), 1453-1464, 2009 | 1376 | 2009 |
| CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia H Frangoul, D Altshuler, MD Cappellini, YS Chen, J Domm, BK Eustace, ... New England Journal of Medicine 384 (3), 252-260, 2021 | 1213 | 2021 |
| Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy E Sotillo, DM Barrett, KL Black, A Bagashev, D Oldridge, G Wu, ... Cancer discovery 5 (12), 1282-1295, 2015 | 1188 | 2015 |
| Antibody-modified T cells: CARs take the front seat for hematologic malignancies MV Maus, SA Grupp, DL Porter, CH June Blood, The Journal of the American Society of Hematology 123 (17), 2625-2635, 2014 | 1047 | 2014 |
| Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia DT Teachey, SF Lacey, PA Shaw, JJ Melenhorst, SL Maude, N Frey, ... Cancer discovery 6 (6), 664-679, 2016 | 983 | 2016 |
| Managing cytokine release syndrome associated with novel T cell-engaging therapies SL Maude, D Barrett, DT Teachey, SA Grupp The Cancer Journal 20 (2), 119-122, 2014 | 836 | 2014 |
| Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia KG Roberts, RD Morin, J Zhang, M Hirst, Y Zhao, X Su, SC Chen, ... Cancer cell 22 (2), 153-166, 2012 | 834 | 2012 |
| ‘Off-the-shelf’allogeneic CAR T cells: development and challenges S Depil, P Duchateau, SA Grupp, G Mufti, L Poirot Nature reviews Drug discovery 19 (3), 185-199, 2020 | 804 | 2020 |
| CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia SL Maude, DT Teachey, DL Porter, SA Grupp Blood, The Journal of the American Society of Hematology 125 (26), 4017-4023, 2015 | 804 | 2015 |
| Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy DT Teachey, SR Rheingold, SL Maude, G Zugmaier, DM Barrett, AE Seif, ... Blood, The Journal of the American Society of Hematology 121 (26), 5154-5157, 2013 | 660 | 2013 |
| Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies M Ruella, DM Barrett, SS Kenderian, O Shestova, TJ Hofmann, ... The Journal of clinical investigation 126 (10), 3814-3826, 2016 | 584 | 2016 |
Carl JuneUniversity of PennsylvaniaVerified email at upenn.edu
